Fahriye Seçil Tecellioğlu

Fahriye Seçil Tecellioğlu

Auto-generated profile, based on publicly available information

Fahriye Seçil Tecellioğlu

Department of Medical Pathology, Malatya Turgut Ozal University Faculty of Medicine, Malatya, Türkiye

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2025 in The European Research Journal
Verified
Journal Article
Open access
PDF file
HEHatice Elmas
Hatice Elmas
AUAysun Uğuz
Aysun Uğuz
AŞAbdullah Fahri Şahin
Abdullah Fahri Şahin
FTFahriye Seçil Tecellioğlu
Fahriye Seçil Tecellioğlu
PWPD Dr. med. Lutz Welker
PD Dr. med. Lutz Welker
Lung cancer is a highly heterogeneous disease that presents significant challenges in accurate diagnosis and classification due to its diverse histological and molecular characteristics. Traditional diagnostic methods, while valuable, are often limited by invasiveness, subjectivity, and an inability to fully capture tumor complexity. Recent advancements in artificial intelligence (AI), machine learning, and radiomics have transformed the field, offering enhanced precision, efficiency, and objectivity in lung cancer classification. These technologies enable detailed analyses of imaging data, histopathological findings, and molecular profiles, facilitating improved subtype identification, outcome prediction, and personalized treatment strategies. Cytopathology remains a cornerstone of lung cancer diagnostics, particularly for small biopsies and cytological samples, which are often the only materials available in advanced stages. The integration of AI-driven methods into cytopathology and radiomics workflows has shown substantial potential to overcome the limitations of traditional approaches, reduce interobserver variability, and accelerate the diagnostic process. This review underscores the transformative role of AI and radiomics in lung cancer management, highlighting their synergy in advancing precision oncology. As ongoing research continues to refine these methodologies, the future of lung cancer care is poised for significant advancements, offering improved diagnostic accuracy, personalized therapies, and better patient outcomes.